541 related articles for article (PubMed ID: 32587094)
1. SARS-CoV-2 (COVID-19) structural and evolutionary dynamicome: Insights into functional evolution and human genomics.
Gupta R; Charron J; Stenger CL; Painter J; Steward H; Cook TW; Faber W; Frisch A; Lind E; Bauss J; Li X; Sirpilla O; Soehnlen X; Underwood A; Hinds D; Morris M; Lamb N; Carcillo JA; Bupp C; Uhal BD; Rajasekaran S; Prokop JW
J Biol Chem; 2020 Aug; 295(33):11742-11753. PubMed ID: 32587094
[TBL] [Abstract][Full Text] [Related]
2. SARS-CoV2 (COVID-19) Structural/Evolution Dynamicome: Insights into functional evolution and human genomics.
Gupta R; Charron J; Stenger CL; Painter J; Steward H; Cook TW; Faber W; Frisch A; Lind E; Bauss J; Li X; Sirpilla O; Soehnlen X; Underwood A; Hinds D; Morris M; Lamb N; Carcillo JA; Bupp C; Uhal BD; Rajasekaran S; Prokop JW
bioRxiv; 2020 May; ():. PubMed ID: 32511397
[TBL] [Abstract][Full Text] [Related]
3. ACE2 and TMPRSS2 Potential Involvement in Genetic Susceptibility to SARS-COV-2 in Cancer Patients.
Ravaioli S; Tebaldi M; Fonzi E; Angeli D; Mazza M; Nicolini F; Lucchesi A; Fanini F; Pirini F; Tumedei MM; Cerchione C; Viale P; Sambri V; Martinelli G; Bravaccini S
Cell Transplant; 2020; 29():963689720968749. PubMed ID: 33108902
[TBL] [Abstract][Full Text] [Related]
4. Dynamics of the ACE2-SARS-CoV-2/SARS-CoV spike protein interface reveal unique mechanisms.
Ali A; Vijayan R
Sci Rep; 2020 Aug; 10(1):14214. PubMed ID: 32848162
[TBL] [Abstract][Full Text] [Related]
5. Investigation of the genetic variation in ACE2 on the structural recognition by the novel coronavirus (SARS-CoV-2).
Guo X; Chen Z; Xia Y; Lin W; Li H
J Transl Med; 2020 Aug; 18(1):321. PubMed ID: 32831104
[TBL] [Abstract][Full Text] [Related]
6. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Hoffmann M; Kleine-Weber H; Schroeder S; Krüger N; Herrler T; Erichsen S; Schiergens TS; Herrler G; Wu NH; Nitsche A; Müller MA; Drosten C; Pöhlmann S
Cell; 2020 Apr; 181(2):271-280.e8. PubMed ID: 32142651
[TBL] [Abstract][Full Text] [Related]
7. Optimized Pseudotyping Conditions for the SARS-COV-2 Spike Glycoprotein.
Johnson MC; Lyddon TD; Suarez R; Salcedo B; LePique M; Graham M; Ricana C; Robinson C; Ritter DG
J Virol; 2020 Oct; 94(21):. PubMed ID: 32788194
[TBL] [Abstract][Full Text] [Related]
8. Broad host range of SARS-CoV-2 predicted by comparative and structural analysis of ACE2 in vertebrates.
Damas J; Hughes GM; Keough KC; Painter CA; Persky NS; Corbo M; Hiller M; Koepfli KP; Pfenning AR; Zhao H; Genereux DP; Swofford R; Pollard KS; Ryder OA; Nweeia MT; Lindblad-Toh K; Teeling EC; Karlsson EK; Lewin HA
Proc Natl Acad Sci U S A; 2020 Sep; 117(36):22311-22322. PubMed ID: 32826334
[TBL] [Abstract][Full Text] [Related]
9. Composition and divergence of coronavirus spike proteins and host ACE2 receptors predict potential intermediate hosts of SARS-CoV-2.
Liu Z; Xiao X; Wei X; Li J; Yang J; Tan H; Zhu J; Zhang Q; Wu J; Liu L
J Med Virol; 2020 Jun; 92(6):595-601. PubMed ID: 32100877
[TBL] [Abstract][Full Text] [Related]
10. Comparison of Severe Acute Respiratory Syndrome Coronavirus 2 Spike Protein Binding to ACE2 Receptors from Human, Pets, Farm Animals, and Putative Intermediate Hosts.
Zhai X; Sun J; Yan Z; Zhang J; Zhao J; Zhao Z; Gao Q; He WT; Veit M; Su S
J Virol; 2020 Jul; 94(15):. PubMed ID: 32404529
[TBL] [Abstract][Full Text] [Related]
11. The Proteins of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS CoV-2 or n-COV19), the Cause of COVID-19.
Yoshimoto FK
Protein J; 2020 Jun; 39(3):198-216. PubMed ID: 32447571
[TBL] [Abstract][Full Text] [Related]
12. In silico study of azithromycin, chloroquine and hydroxychloroquine and their potential mechanisms of action against SARS-CoV-2 infection.
Braz HLB; Silveira JAM; Marinho AD; de Moraes MEA; Moraes Filho MO; Monteiro HSA; Jorge RJB
Int J Antimicrob Agents; 2020 Sep; 56(3):106119. PubMed ID: 32738306
[TBL] [Abstract][Full Text] [Related]
13. SARS-CoV-2 binds platelet ACE2 to enhance thrombosis in COVID-19.
Zhang S; Liu Y; Wang X; Yang L; Li H; Wang Y; Liu M; Zhao X; Xie Y; Yang Y; Zhang S; Fan Z; Dong J; Yuan Z; Ding Z; Zhang Y; Hu L
J Hematol Oncol; 2020 Sep; 13(1):120. PubMed ID: 32887634
[TBL] [Abstract][Full Text] [Related]
14. SARS-CoV-2 pandemic and research gaps: Understanding SARS-CoV-2 interaction with the ACE2 receptor and implications for therapy.
Datta PK; Liu F; Fischer T; Rappaport J; Qin X
Theranostics; 2020; 10(16):7448-7464. PubMed ID: 32642005
[TBL] [Abstract][Full Text] [Related]
15. Role of the GTNGTKR motif in the N-terminal receptor-binding domain of the SARS-CoV-2 spike protein.
Behloul N; Baha S; Shi R; Meng J
Virus Res; 2020 Sep; 286():198058. PubMed ID: 32531235
[TBL] [Abstract][Full Text] [Related]
16. SARS-CoV-2 host tropism: An in silico analysis of the main cellular factors.
Rangel HR; Ortega JT; Maksoud S; Pujol FH; Serrano ML
Virus Res; 2020 Nov; 289():198154. PubMed ID: 32918944
[TBL] [Abstract][Full Text] [Related]
17. Structural and functional modelling of SARS-CoV-2 entry in animal models.
Brooke GN; Prischi F
Sci Rep; 2020 Sep; 10(1):15917. PubMed ID: 32985513
[TBL] [Abstract][Full Text] [Related]
18. Enhanced Binding of SARS-CoV-2 Spike Protein to Receptor by Distal Polybasic Cleavage Sites.
Qiao B; Olvera de la Cruz M
ACS Nano; 2020 Aug; 14(8):10616-10623. PubMed ID: 32806067
[TBL] [Abstract][Full Text] [Related]
19. Synergistic antiviral effect of hydroxychloroquine and azithromycin in combination against SARS-CoV-2: What molecular dynamics studies of virus-host interactions reveal.
Fantini J; Chahinian H; Yahi N
Int J Antimicrob Agents; 2020 Aug; 56(2):106020. PubMed ID: 32405156
[TBL] [Abstract][Full Text] [Related]
20. An integrated drug repurposing strategy for the rapid identification of potential SARS-CoV-2 viral inhibitors.
Trezza A; Iovinelli D; Santucci A; Prischi F; Spiga O
Sci Rep; 2020 Aug; 10(1):13866. PubMed ID: 32807895
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
